Chloe Yang

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: June 15, 2026

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third-Line CAR T.

Journal: Hematological oncology

Published: November 03, 2025

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.

Journal: European journal of haematology

Published: October 09, 2025

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Journal: Blood cancer discovery

Published: September 30, 2025

Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.

Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma.

Journal: Blood advances

Published: June 09, 2025

Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphoma.

Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphoma.

Journal: Blood advances

Published: June 09, 2025

Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy.

Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy.

Journal: Blood neoplasia

Published: May 09, 2025

Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada.

Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada.

Journal: Leukemia & lymphoma

Published: February 22, 2025

A Single-Center Study on Frontline Treatment for Multiple Myeloma Patients With 1q Abnormalities.

A Single-Center Study on Frontline Treatment for Multiple Myeloma Patients With 1q Abnormalities.

Journal: EJHaem

Published: November 14, 2024

Very late relapse in Hodgkin lymphoma: Characterizing an understudied population.

Very late relapse in Hodgkin lymphoma: Characterizing an understudied population.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 14, 2023

Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.

Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.

Journal: Journal of clinical apheresis

Published: June 09, 2021

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study.

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study.

Journal: Journal of the International AIDS Society

Published: November 15, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026